Ejk Adu1, E Ampadu, D Acheampong. 1. Department of Surgery, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. aduemmanuel@hotmail.com
Abstract
BACKGROUND: Mycobacterium ulcerans (MU) disease causes extensive destruction of tissues leaving large ulcers on the body. Management which consisted of surgical excision of the lesions is gradually being replaced with chemotherapy. OBJECTIVE: To study the impact on surgery of prior treatment of MU disease with rifampicin and streptomycin. STUDY DESIGN: Retrospective, from September 2004 to September 2009. SETTING: Asunafo, Amansie West, Ahafo Ano and Amansie Central districts of Ghana. METHODS: Patients who have completed 8 weeks or a minimum of 4 weeks treatment with rifampicin and streptomycin but have unhealed lesions were selected for surgery. RESULTS: 132 patients had surgery for MU disease; 51 at Tepa (Ahafo Ano); 36 at Agroyesum (Amansie West); 16 from Jacobu (Amansie Central); 29 from Goaso (Asunafo) districts. Their ages ranged from 4 to 98 years, with mean age of 29.90 years, standard deviation of 20.74. Sites involved were: head and neck 1 (0.74%), upper limb 40 (29.63%), lower limb 92 (68.15%), trunk 2 (1.48%) (N=135). The clinical forms were: papule 1 (0.74%), nodule 2 (1.48%), oedematous lesion 4 (2.96%), osteomyelitis 2 (1.48%), ulcers 124 (91.85%), contractures 2 (1.48%). 139 surgical procedures were performed: excision 25 (18.11), skin grafting 36 (26.1%), excision and skin grafting 54 (39.1%), debridem net 10 (7.2%), sequestrectomy 2 (1.4%), regrafting 10 (7.2%), release of contractures 2 (1.4%). CONCLUSION: Treatment of MU disease with rifampicin and streptomycin improved the condition and minimised the extent of surgery. Combination of surgery and antibiotics is necessary to prevent the development contractures.
BACKGROUND:Mycobacterium ulcerans (MU) disease causes extensive destruction of tissues leaving large ulcers on the body. Management which consisted of surgical excision of the lesions is gradually being replaced with chemotherapy. OBJECTIVE: To study the impact on surgery of prior treatment of MU disease with rifampicin and streptomycin. STUDY DESIGN: Retrospective, from September 2004 to September 2009. SETTING: Asunafo, Amansie West, Ahafo Ano and Amansie Central districts of Ghana. METHODS:Patients who have completed 8 weeks or a minimum of 4 weeks treatment with rifampicin and streptomycin but have unhealed lesions were selected for surgery. RESULTS: 132 patients had surgery for MU disease; 51 at Tepa (Ahafo Ano); 36 at Agroyesum (Amansie West); 16 from Jacobu (Amansie Central); 29 from Goaso (Asunafo) districts. Their ages ranged from 4 to 98 years, with mean age of 29.90 years, standard deviation of 20.74. Sites involved were: head and neck 1 (0.74%), upper limb 40 (29.63%), lower limb 92 (68.15%), trunk 2 (1.48%) (N=135). The clinical forms were: papule 1 (0.74%), nodule 2 (1.48%), oedematous lesion 4 (2.96%), osteomyelitis 2 (1.48%), ulcers 124 (91.85%), contractures 2 (1.48%). 139 surgical procedures were performed: excision 25 (18.11), skin grafting 36 (26.1%), excision and skin grafting 54 (39.1%), debridem net 10 (7.2%), sequestrectomy 2 (1.4%), regrafting 10 (7.2%), release of contractures 2 (1.4%). CONCLUSION: Treatment of MU disease with rifampicin and streptomycin improved the condition and minimised the extent of surgery. Combination of surgery and antibiotics is necessary to prevent the development contractures.
Authors: S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Willemien A Nienhuis; Ymkje Stienstra; William A Thompson; Peter C Awuah; K Mohammed Abass; Wilson Tuah; Nana Yaa Awua-Boateng; Edwin O Ampadu; Vera Siegmund; Jan P Schouten; Ohene Adjei; Gisela Bretzel; Tjip S van der Werf Journal: Lancet Date: 2010-02-03 Impact factor: 79.321
Authors: George Amofah; Frank Bonsu; Christopher Tetteh; Jane Okrah; Kwame Asamoa; Kingsley Asiedu; Jonathan Addy Journal: Emerg Infect Dis Date: 2002-02 Impact factor: 6.883
Authors: B J Marston; M O Diallo; C R Horsburgh; I Diomande; M Z Saki; J M Kanga; G Patrice; H B Lipman; S M Ostroff; R C Good Journal: Am J Trop Med Hyg Date: 1995-03 Impact factor: 2.345
Authors: Samuel Yaw Aboagye; Prince Asare; Isaac Darko Otchere; Eric Koka; George Ekow Mensah; Dzidzo Yirenya-Tawiah; Dorothy Yeboah-Manu Journal: Am J Trop Med Hyg Date: 2017-05 Impact factor: 2.345
Authors: Martin W Bratschi; Miriam Bolz; Jacques C Minyem; Leticia Grize; Fidèle G Wantong; Sarah Kerber; Earnest Njih Tabah; Marie-Thérèse Ruf; Ferdinand Mou; Djeunga Noumen; Alphonse Um Boock; Gerd Pluschke Journal: PLoS Negl Trop Dis Date: 2013-06-13
Authors: Anita C Wadagni; Jonathan Steinhorst; Yves T Barogui; P M Catraye; Ronald Gnimavo; Kabiru M Abass; George Amofa; Michael Frimpong; Francisca N Sarpong; Tjip S van der Werf; Richard Phillips; Ghislain E Sopoh; Christian R Johnson; Ymkje Stienstra Journal: PLoS Negl Trop Dis Date: 2019-10-28